• Nkarta (NASDAQ:NKTX) is ending development of NKX019 in non-Hodgkin lymphoma. However, the candidate will continue to advance for autoimmune disease indications.
• The company said that the decision was made based on an assessment of the latest group of large B-cell lymphoma patients in a trial.
• NKX019 targets the CD19 protein. It is currently in the clinic under examination as a lupus treatment.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。